FMP
NASDAQ
Nuvectis Pharma, Inc., a biopharmaceutical company, focuses on the development of precision medicines for the treatment of serious unmet medical needs in oncology. It develops NXP800, a novel heat shock factor 1 pathway inhibitor for the treatment of various cancers; and NXP900, a small molecule drug candidate to inhibit the Proto-oncogene c-Src and YES1 kinases. The company was incorporated in 2020 and is based in Fort Lee, New Jersey.
6.82 USD
0.1 (1.47%)
Valuation Date:
Apr 19, 2024 4:00 PM
Share Price on Valuation Date
$6.82
Stock Beta
0.27
Shares Outstanding
17768824